article thumbnail

ICYMI: Cancer death rate continues to decline due to treatment advances

PhRMA

This report is the latest to document this progress. One study found, between 2000 and 2016 alone, new cancer medicines were associated with nearly 1.3 The report notes the continued decline in death rates since 1991, including a 1.5% million averted cancer deaths across the 15 most common tumor types.

article thumbnail

FDA sends warning letter to KVK-Tech manufacturing facility

European Pharmaceutical Review

The document identified significant violations of current good manufacturing practice (cGMP) regulations for finished pharmaceuticals. Inadequate validation of test methods : KVK-Tech failed to establish and document the accuracy, sensitivity, specificity and reproducibility of test methods.

FDA 88
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Pharmalittle: We’re reading about FDA guidance on AI, meds releasing ‘forever chemicals,’ and more

STAT

As of last October, the agency had received more than 500 drug submissions with AI components going back to 2016, with a large number in the areas of oncology, neurology, and gastroenterology.

FDA 100
article thumbnail

Intercept's Ocaliva approval in jeopardy after FDA flags concerns in advisory committee briefing doc

Fierce Pharma

. | Ahead of an advisory committee meeting slated for Friday, the FDA unleashed damning briefing documents calling into question the effectiveness and safety of Intercept’s rare liver disease drug Ocaliva.

FDA 85
article thumbnail

STAT+: DaVita faces another probe over ties to kidney care charity

STAT

attorney general is specifically looking at “communications with AKF, documents relating to donations to the AKF, and communications with patients, providers, and insurers regarding the AKF.” ” The probe covers everything from January 2016 to the present day. Continue to STAT+ to read the full story…

article thumbnail

STAT+: A ‘disaster’, or a ‘clear path’ forward?: New FDA guidance on AI in medicine sparks strong reactions

STAT

One medical device lawyer wrote that the document “violates” the 21st Century Cures Act passed by Congress in 2016 to exempt certain software products from regulatory review. But they are sharply divided on whether that’s a much-needed change, or a dramatic overreach by regulators.

FDA 98
article thumbnail

Top 10 Journal Articles To Read During Your Infectious Diseases Pharmacy Rotation

IDStewardship

It’s from 2016 about the future of antibiotics and resistance, but it remains highly relevant today and people consistently give positive feedback about it. Memorizing 45+ page document is certainly not a reasonable expectation, but one can certainly walk away with an awareness of general concepts and themes which are relevant.